Clinical Trial Update: AUY922 With Lapatinib and Letrozole for ER+ HER2+ Advanced Breast Cancer [Phase 1, Phase 2]

View source ↗

Summary

A Phase 1/2 trial of AUY922 in combination with lapatinib and letrozole for ER-positive, HER2-positive advanced breast cancer has been withdrawn from the study.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer
• Her-2 Positive Breast Cancer

Drugs mentioned

• AUY922 (luminespib)
• Lapatinib (Lapatinib)
• Letrozole (letrozole)

Snippet

Sponsor: Texas Tech University Health Sciences Center, El Paso | Conditions: Breast Cancer, Metastatic Breast Cancer | Phase 1, Phase 2 | Status: WITHDRAWN